DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 12/03/2019 --Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report

1. Hidradenitis Suppurativa total prevalent population in 7MM was found to be 6,851,308 in 2017.
2. Among all the countries, the United States accounts for the highest Hidradenitis Suppurativa prevalent population with 3,271,104 prevalent cases in the United States in 2017.
3. In 2017, there were 2,414,075, Hidradenitis Suppurativa prevalent cases in women and 857,029 prevalent cases in men in the United States.
4. Among the European countries, Germany had the highest prevalent population of Hidradenitis Suppurativa with 832,312 cases, followed by France in 2017. On the other hand, Spain had the lowest prevalent population in 2017.

Key benefits of the report

1. Hidradenitis Suppurativa market report covers a descriptive overview and comprehensive insight of the Hidradenitis Suppurativa epidemiology and Hidradenitis Suppurativa market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Hidradenitis Suppurativa market report provides insights on the current and emerging therapies.
3. Hidradenitis Suppurativa market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Hidradenitis Suppurativa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa market.

Request for sample pages

"Hidradenitis Suppurativa is more common (three times) in women than men."

Global burden of Hidradenitis Suppurativa has increased over the years. Among the 7 major markets, the United States has reported having maximum Hidradenitis Suppurativa prevalent cases. The therapeutic Hidradenitis Suppurativa market in the 7MM was found to be USD 718.3 million in 2017.

In the US, Hidradenitis Suppurativa market size was USD 406.3 million in 2017. Among EU5 countries, the market size of Germany was found to be highest with USD 67.9 million, while Spain had the lowest market size of Hidradenitis Suppurativa in 2017. In addition, the therapeutic Hidradenitis Suppurativa market size in Japan was USD 61.6 million in 2017.

Current treatment approaches depend on severity and clinical staging. There are a number of lifestyle modifications recommended, such as smoking cessation, weight loss and stress management, but there is little evidence regarding their efficacy. A variety of pharmacologic treatments have been used, with varying degrees of success, including topical and systemic antibiotics, corticosteroids, anti-androgen therapy, systemic retinoids and immunosuppressive agents including biologics (Humira, Infliximab). The mainstay of medical treatment of mild disease involves anti-bacterial washes and topical antibiotics. Acute flares may be managed by intralesional corticosteroids and/or minor surgical procedures. Oral therapies for mild to moderate Hidradenitis Suppurativa include extended courses of broad-spectrum antibiotics, oral anti-androgens, and systemic retinoids. Metformin has been used to treat metabolic syndrome associated with Hidradenitis Suppurativa and has been reported to be effective in reducing Hidradenitis Suppurativa disease activity in a small study.

Overall, the global Hidradenitis Suppurativa therapeutics market has increased over the past few years. The Hidradenitis Suppurativa market size is further expected to increase by the major drivers such as rising prevalent population, technological advancements and upcoming therapies in the forecast period [2017-2028].

The launch of the emerging therapies is expected to significantly impact Hidradenitis Suppurativa treatment scenario in the upcoming years:-
Drugs covered
1. IFX-1
2. INCB054707
3. Avacopan
4. MABp1
5. Cosentyx etc.
And many others

The key players in Hidradenitis Suppurativa market are:
1. InflaRx
2. Incyte Corporation
3. ChemoCentryx
4. XBiotech
5. Celgene
6. Novartis
And many others

Table of contents

1. Key Insights
2. Hidradenitis Suppurativa Market Overview at a Glance
3. Hidradenitis Suppurativa Disease Overview
4. Hidradenitis Suppurativa Epidemiology and Patient Population
5. Hidradenitis Suppurativa Country Wise-Epidemiology
5.1. United States
5.2. EU5
5.2.1.Assumptions and Rationale
5.2.2.Germany
5.2.3.UK
5.2.4.France
5.2.5.Italy
5.2.6.Spain
5.3. Japan
6. Hidradenitis Suppurativa Current Treatment Practices
7. Unmet Needs
8. Hidradenitis Suppurativa Marketed Drugs
8.1. Humira: AbbVie
9. Hidradenitis Suppurativa Emerging Therapies
9.1. Key Cross of Emerging Therapies
9.2. IFX-1: InflaRx
9.3. Cosentyx (Secukinumab): Novartis Pharmaceuticals
9.4. MABp1 (Bermekimab): XBiotech, Inc.
9.5. Avacopan: ChemoCentryx
10. Hidradenitis Suppurativa 7 Major Market Analysis
11. Market Outlook by Country
12. The United States: Market Outlook
13. EU-5 Countries: Market Outlook
13.1. Germany Market Size
13.2. France Market Size
13.3. Italy Market Size
13.4. United Kingdom Market Size
13.5. Spain Market Size
14. Japan: Market Outlook
14.1. Japan Market Size
15. Market Drivers
16. Market Barriers
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight